ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $22,596,000 | -61.1% | 234,591 | -53.5% | 8.61% | -53.0% |
| Q2 2019 | $58,060,000 | -2.2% | 504,210 | 0.0% | 18.30% | +5.4% |
| Q1 2019 | $59,346,000 | +87.9% | 504,210 | 0.0% | 17.36% | +28.1% |
| Q4 2018 | $31,589,000 | -11.6% | 504,210 | 0.0% | 13.56% | +42.1% |
| Q3 2018 | $35,728,000 | +6.5% | 504,210 | 0.0% | 9.54% | -5.0% |
| Q2 2018 | $33,540,000 | -12.5% | 504,210 | -14.0% | 10.04% | +8.5% |
| Q1 2018 | $38,337,000 | -14.0% | 586,195 | -47.3% | 9.25% | -13.4% |
| Q4 2017 | $44,587,000 | -5.3% | 1,113,014 | -14.3% | 10.69% | -17.9% |
| Q3 2017 | $47,091,000 | +72.0% | 1,299,052 | +31.7% | 13.01% | +19.0% |
| Q2 2017 | $27,385,000 | +20.5% | 986,492 | +21.6% | 10.94% | +17.7% |
| Q1 2017 | $22,722,000 | +55.7% | 811,492 | +12.5% | 9.30% | +32.8% |
| Q4 2016 | $14,596,000 | +0.7% | 721,152 | 0.0% | 7.00% | -5.9% |
| Q3 2016 | $14,495,000 | +51.5% | 721,152 | 0.0% | 7.44% | +28.8% |
| Q2 2016 | $9,570,000 | -28.5% | 721,152 | 0.0% | 5.78% | -34.4% |
| Q1 2016 | $13,377,000 | +1.2% | 721,152 | 0.0% | 8.80% | -18.9% |
| Q4 2015 | $13,212,000 | – | 721,152 | – | 10.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |